Wells Fargo’s Moleculin Biotech MBRX Stock Holding History

Wells Fargo’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$558	Buy	+10	New	+$511	﹤0.01%	6510
2024 Q2	–	Hold	0	–	-$112	–	7234
2024 Q1	–	Hold	0	–	–	–	6626
2023 Q4	–	Hold	0	–	–	–	6615
2023 Q3	–	Hold	0	–	–	–	6472
2023 Q2	–	Hold	0	–	–	–	6826
2023 Q1	–	Hold	0	–	–	–	6788
2022 Q4	–	Hold	0	–	–	–	6361
2022 Q3	–	Hold	0	–	–	–	7080
2022 Q2	–	Sell	-1	Closed	-$11.6K	–	7213
2022 Q1	$7K	Hold	1	–	–	﹤0.01%	6386
2021 Q4	$7K	Buy	+1	New	+$17.7K	﹤0.01%	6638
2021 Q3	–	Hold	0	–	–	–	6740
2021 Q2	–	Hold	0	–	–	–	6691
2021 Q1	–	Hold	0	–	–	–	6740
2020 Q4	–	Sell	-2	Closed	-$71K	–	6795
2020 Q3	$67K	Hold	2	–	–	﹤0.01%	5404
2020 Q2	$76K	Buy	+2	New	+$94.8K	﹤0.01%	5349
2020 Q1	–	Hold	0	–	–	–	6558
2019 Q4	–	Hold	0	–	–	–	6123
2019 Q3	–	Hold	0	–	–	–	6145
2019 Q2	–	Hold	0	–	–	–	6117
2018 Q2	–	Hold	0	–	-$9K	–	6466
2018 Q1	–	Hold	0	–	–	–	5964

Other funds holding MBRX

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wells Fargo's MBRX Position: Q2 2026 in Review

Wells Fargo opened a new position in Moleculin Biotech (MBRX) in Q2 2026: 10 shares worth $558. The stake represents ﹤0.01% of the portfolio and ranks #6510 among its holdings. This is a return to the name: Wells Fargo previously reported a position in MBRX as recently as Q1 2022.

Wells Fargo first reported a position in MBRX in Q2 2020 and has held it in 5 quarters since. The position peaked at $76K in Q2 2020. 15 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

Wells Fargo held 10 shares of Moleculin Biotech worth $558 as of Q2 2026.
Moleculin Biotech was a new Wells Fargo position in Q2 2026.
Moleculin Biotech made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6510 holding.
Wells Fargo first reported a position in Moleculin Biotech in Q2 2020 and has held it in 5 quarters since.
Wells Fargo's Moleculin Biotech position peaked at $76K in Q2 2020.
15 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.